2-Hydroxy-1-<2-carbamoyl-ethyl>-naphthalin | 92028-77-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 2-Hydroxy-1-<2-carbamoyl-ethyl>-naphthalin
• 英文别名: 3-(2-hydroxy-[1]naphthyl)-propionic acid amide；3-(2-Hydroxy-[1]naphthyl)-propionsaeure-amid；3-(2-Hydroxy-naphthyl-(1))-propionamid；3-(2-Hydroxy-1-naphthyl)propanamide；3-(2-hydroxynaphthalen-1-yl)propanamide
• CAS: 92028-77-8
• 化学式: C₁₃H₁₃NO₂
• 分子量: 215.252
• InChiKey: ARFRNBQNIMKECT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-Hydroxy-1-<2-carbamoyl-ethyl>-naphthalin 、 硫酸二甲酯 生成 3-(2-methoxy-[1]naphthyl)-propionic acid amide
  参考文献：
  名称：

  PREPARATION AND REDUCTION OF 2-METHOXY-N-METHYL-1-NAPHTHALENEËTHYLAMINE¹

  摘要：

  DOI：

  10.1021/jo01126a017
• 作为产物：
  描述：

  2-羟基-2-(2-萘基)丙酸 在 氨 、 甲苯 、 苯 作用下， 生成 2-Hydroxy-1-<2-carbamoyl-ethyl>-naphthalin
  参考文献：
  名称：

  The Preparation and Some Reactions of α-(ι-Cyanoethyl)-β-naphthol

  摘要：

  DOI：

  10.1021/ja01186a036

文献信息

• Inhibitors of Sir2:  Evaluation of Splitomicin Analogues
  作者：Jeff Posakony、Maki Hirao、Sam Stevens、Julian A. Simon、Antonio Bedalov

  DOI：10.1021/jm030473r

  日期：2004.5.1

  Splitomicin (1) and 41 analogues were prepared and evaluated in cell-based Sir2 inhibition and toxicity assays and an in vitro Sir2 inhibition assay. Lactone ring or naphthalene (positions 7-9) substituents decrease activity, but other naphthalene substitutions (positions 5 and 6) are well-tolerated. The hydrolytically unstable aromatic lactone is important for activity. Lactone hydrolysis rates were used as a measure of reactivity; hydrolysis rates correlate with inhibitory activity. The most potent Sir2 inhibitors were structurally similar to and had hydrolysis rates similar to 1.
• METHODS FOR TREATING POLYCYSTIC KIDNEY DISEASE (PKD) OR OTHER CYST FORMING DISEASES
  申请人：Li Rong

  公开号：US20120122787A1

  公开（公告）日：2012-05-17

  The present invention is directed to, inter alia, methods of treating or ameliorating an effect of a polycystic disease. This method include administering to a patient in need thereof an amount of a modulator of a histone deacetylase (HDAC) path-way, which is sufficient to treat or ameliorate an effect of a polycystic disease, particularly a polycystic kidney disease.
• [EN] METHODS FOR TREATING POLYCYSTIC KIDNEY DISEASE (PKD) OR OTHER CYST FORMING DISEASES<br/>[FR] PROCÉDÉS POUR TRAITER UNE MALADIE RÉNALE POLYKYSTIQUE (PKD) OU D’AUTRES MALADIES DE FORMATION DE KYSTES
  申请人：STOWERS INST FOR MEDICAL RES

  公开号：WO2011006040A2

  公开（公告）日：2011-01-13

  The present invention is directed to, inter alia, methods of treating or ameliorating an effect of a polycystic disease. This method include administering to a patient in need thereof an amount of a modulator of a histone deacetylase (HDAC) pathway, which is sufficient to treat or ameliorate an effect of a polycystic disease, particularly a polycystic kidney disease.
• The Preparation and Some Reactions of α-(ι-Cyanoethyl)-β-naphthol
  作者：A. F. Hardman

  DOI：10.1021/ja01186a036

  日期：1948.6
• PREPARATION AND REDUCTION OF 2-METHOXY-N-METHYL-1-NAPHTHALENEËTHYLAMINE¹
  作者：C. F. KOELSCH、HORACE E. HOOD

  DOI：10.1021/jo01126a017

  日期：1955.9